Business
Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership
LOS ANGELES, CA - March 27, 2026 (NEWMEDIAWIRE) - Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. T...
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"text","content":"LOS ANGELES, CA - March 27, 2026 (NEWMEDIAWIRE) - Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company's lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.","length":691,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"These developments position the company at the intersection of innovation and therapeutics","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":393,"olType":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1293,"height":507,"url":"https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G2DGi3R0hbPlBxZDZhHCXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3Ng--/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JrcIiL04ET0fk6Rf6Zw0cQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDI-/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":1200,"height":471}}},{"type":"text","content":"The company recently announced a partnership with Liora Technologies, setting the company up to be a leading force in multimodal oncology data integration. This partnership uses foundation model-based embeddings t...